[Form 4] Kura Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Medical Officer Mollie Leoni reported new equity awards. On 01/02/2026 she received 50,000 shares of common stock in the form of restricted stock units at a stated price of $0, increasing her directly held common stock to 275,454 shares. The RSUs vest in four equal annual installments on 1/26/2027, 1/26/2028, 1/26/2029 and 1/26/2030, tying the award to multi‑year service.

She was also granted an option to purchase 100,000 shares of common stock at an exercise price of $10.335. This stock option vests in 48 equal monthly installments starting on the grant date and is exercisable until 01/01/2036, providing long-term, performance-linked compensation.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Leoni Mollie

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	100,000	$0.00	--
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Option to purchase common stock — 100,000 shares (Direct); Common Stock — 275,454 shares (Direct)

Footnotes (1)

1. Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. This option vests in 48 equal monthly installments commencing on the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leoni Mollie

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		50,000(1)	A	$0	275,454	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$10.335	01/02/2026		A		100,000		(2)	01/01/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30.

2. This option vests in 48 equal monthly installments commencing on the grant date.

	Teresa Bair, Attorney-in-fact for Mollie Leoni	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did KURA Chief Medical Officer Mollie Leoni report?

Mollie Leoni reported equity compensation awards consisting of 50,000 restricted stock units of Kura Oncology, Inc. common stock and a stock option to purchase 100,000 shares.

How many Kura Oncology (KURA) shares does the CMO own after this Form 4 filing?

Following the reported transaction, Mollie Leoni beneficially owned 275,454 shares of Kura Oncology common stock directly.

What are the vesting terms of the 50,000 KURA restricted stock units?

The 50,000 RSUs granted to Mollie Leoni vest in four equal annual installments on 1/26/2027, 1/26/2028, 1/26/2029 and 1/26/2030.

What are the key terms of the 100,000-share Kura Oncology stock option?

The option covers 100,000 shares of Kura Oncology common stock at an exercise price of $10.335 and is exercisable until 01/01/2036.

How does the 100,000-share option granted to the KURA CMO vest?

The stock option granted to Mollie Leoni vests in 48 equal monthly installments commencing on the grant date of 01/02/2026.

Were the Kura Oncology (KURA) insider awards classified as direct or indirect ownership?

The Form 4 lists both the 50,000-share RSU grant and the 100,000-share stock option as held under direct (D) ownership by Mollie Leoni.